reason report
scale diversifi tool portfolio help covid time
bottom line remain outperform-r given
view compani life scienc tool lst leader
unmatch scale reach research lab combin
number growth product serv key end-market grow
consolid posit post solid quarter org growth
high end pre-announc org growth
includ estim net impact covid mostli apac
org revenue guid flat posit vs org
declin estim drive stock higher analyt instrument ai
mid-teen larg china expect ai
continu see signific declin sequenti recoveri
life scienc org growth qtr pharma/biotech
hsd continu lead way help test
tailwind quarter believ recoveri
hing length gov shutdown pace recoveri
normal level research return lab overal
believ well-posit given scale strong manag
team emerg even stronger industri leader post crisi
diversifi portfolio weather storm accru
busi share gain ceo marc casper confid team
abil navig crisi explain busi
low-single-digit last global recess
aid global respons mani way includ
ramp product kit detect viru larg instal
base pcr instrument protect healthcar personnel
pp lp segment support pharma/biotech develop
new therapeut via pantheon/bramm pharma servic
offer lead better relationship gov leader around
world like benefit stand industri mani year
end custom health play expect pharma/
lead way preview link expect
pharma/biotech sale resili management
confirm bioproduct busi see strong activ addit
elev research activ pharma/biotech focus
healthcar dx mix bag increas covid-rel busi
off-set decreas regular healthcar commerc academ gov
industri sector experienc greater impact highli
lever gov shelter-in-plac restrict china weigh
sector begin open part economi
activ management note univers research lab
show increas activ expect fare better vs peer lt
given broadest net catch benefit increas research
fund rapid recoveri follow crisi link
compani inform svb leerink llc research
revenu ep exclud charg amort intang
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
pleas refer page import disclosur price chart analyst certif
wide rang speak uncertainti although
expect gain share emerg crisi
manag guid rang growth incorpor
tailwind headwind underli busi
tailwind test new trial expect add
growth off-set headwind shutdown
reduc custom activ end result depend number
factor includ speed gov restrict lift
pace recoveri custom demand activ return
normal prior org growth estim move
reflect management commentari org growth rest year remain
larg unchang put new org growth estim
prior ep move lower reflect margin
pressur previous estim move
target price increas base ev ebitda multipl
appli ebitda estim
rate thermo fisher scientif outperform price target
remain outperform-r given view compani life scienc tool
lst leader unmatch scale reach research lab market combin
number growth product serv key end-market also acquir view
consolid sizabl portion lst market patheon acquisit close
brammer also close believ potenti consolid contract
develop manufactur organ industri long term view
posit given sheer scale reput presenc lst market biopharma
academ channel industrial/environment diagnost deliv manag
forecast grow solidifi presenc emerg market asia-pacif
china revenu continu strength biopharma end-market view
sign slow near term inorgan growth continu remain
key prioriti next five year capit deploy
share current trade ev/ebitda slight premium large-
mid-cap tool averag ev/ebitda
given impress growth deliv leverag biolog drug discoveri
develop product china emerg market tailwind still continu believ
continu hold posit lead lab tool suppli provid like
continu post strong growth expect trade premium large- mid-
cap tool averag deliv ev/ebitda deriv price target
appli multipl ebitda estim
primari risk price target includ
slowdown global budget research could caus downsid risk forecast
tighten budget govern academ fund could result lower revenu
rel estim furthermor restrict global budget could result shift focu
strategi growth could increas oper risk declin government spend
could risk downsid forecast growth nih spend
biopharma declin pose greatest risk tmo revenu declin biopharma fund
could highli impact revenu given third revenu lever biopharma
industri slowdown biopharma fund would result downsid risk estim
valuat biomolecul forecast ramp drug market mid-teen
estim hing prolifer drive use tmo bioprocess
equip mass spectromet instrument reagent character
scale diversif could backfir tmo size diversif
advantag compani consolid space pose signific challeng term
move needl growth perspect given size acquisit
alreadi done includ life pthn transact would ventur estim
deal size least grow north organ make signific move
market although asset might visibl street given limit public
asset larg number privat asset could potenti avail howev
pose risk street might appreci capabl asset enough
move needl
emerg market pose signific risk tmo revenu geopolit risk
emerg market could disrupt oper downsid risk valuat forecast
risk could countri region specif could also impact tmo strategi creat
higher barrier entri exist futur market local product reagent prefer
import oper numer intern market includ india
china eastern europ name
tmo exposur china could also pose concentr risk china repres
tmo revenu macroeconom impact chines market could lead declin
compani revenu regul chines polici could also caus restrict oper
lead lower activ china question remain china relat
detail headwind could emerg polici risk
 synergi may go plan tmo acquisit sizabl may go
plan could result integr risk lower-than-expect synergi integr
requir cultur process adapt synergi model forecast
risk estim remain integr unquantifi aspect target
forecast model margin eros could occur futur acquisit
increas risk amazon distribut busi like impact revenu
tmo laboratori product servic lp busi custom shown
will consid amazon vendor consum product expir
date beaker pipett expect amazon expertis logist suppli chain
allow amazon offer product competit cost thu impact lp revenu overal
disrupt and/or govern mandat shutdown could persist
longer expect impact instrument order consum usag custom
demand may impact short-to-medium term result pandem
dollar million except per share data
good sold
net incom continu op
sg sale
 sale
oper expens sale
compani report svb leerink estim
